Skip to content
Medical Health Aged Care, Research Development

Researching Twins to Better Understand Memory Decline

UNSW Sydney Centre for Healthy Brain Ageing (CHeBA) 2 mins read
Professor Perminder Sachdev AM with participants from CHeBA's Older Australian Twins Study

As people age, they often worry about declining memory and other cognitive abilities.  Many of them will see a doctor, who may do some tests to find out that they are functioning normally.  This is generally referred to as subjective cognitive complaints (SCC). Previous research has shown that some of these individuals indeed progress to mild cognitive impairment and dementia when followed up over several years; however, the majority do not. 

What determines whether someone develops subjective cognitive complaints?  There are both genetic and environmental factors, which are not well understood.  Twins are nature’s experiment to look at genetic vs environmental factors, and a recent research study did just that for subjective cognitive complaints.

The research led by UNSW Sydney’s Centre for Healthy Brain Ageing (CHeBA), and published in the Journal of Alzheimer’s disease, studied over 300 twin pairs from CHeBA’s Older Australian Twins Study with the aim of examining the correlations between these complaints and memory ability, and the influence of personality type and mood on these relationships.

Lead author Dr Amanda Selwood explained that some people have subjective cognitive complaints directly as a result of their personality, with a greater tendency towards negative thoughts or poor mood – even though their memory and thinking are normal for their age.

“In some other people, subjective cognitive complaints can indeed be a sign of true memory impairment and lead to dementia,” said Dr Selwood.

The researchers looked at whether the twin pairs had subjective cognitive complaints, how well they performed on memory tasks, their personality and their mood at the time. 

“Twins are especially valuable for researchers, because identical twins share 100% of their genes, whereas non-identical twins share approximately 50%,” said Dr Selwood.

“Therefore, if identical twins are more likely to both have subjective cognitive complaints than non-identical twins, subjective cognitive complaints are likely to be determined by genetic factors.”

“However, if there is no difference in the similarity between identical and non-identical twins’ subjective cognitive complaints then we can ascertain that they are more likely to be caused by a shared environment.”

The findings indicated that subjective cognitive complaints are moderately heritable – meaning that these complaints are partly influenced by genetic factors. They also found that, when memory performance, mood and personality were factored in, these complaints were linked to memory performance via a genetic pathway and linked to mood via an environmental pathway. 

“Personality appeared to affect subjective cognitive complaints via mood, rather than having a distinct influence of its own,” said Dr Selwood.

“However, memory performance, mood and personality only accounted for some of the genetic factors underlying subjective cognitive complaints.

“Also, we could not clearly differentiate between people who had subjective cognitive complaints due to poor memory performance, and people who had them due to poor mood.”

CHeBA Co-Director and senior author on the research, Professor Perminder Sachdev, said it was important for people to understand that memory concerns are not necessarily an early sign of impeding dementia and that much work is still needed to understand why subjective cognitive complaints occur.

“The take home message is that low mood is often a factor that should be attended to,” said Professor Sachdev. “It is also about attribution. Younger people with memory problems blame inattention and stress. Older people worry about impending dementia.”


Since 2007, the longitudinal Older Australian Twins Study has investigated the genetic and environmental contributions to healthy ageing, in particular ageing in the absence of brain dysfunction and disease, in twins aged 65 years and beyond.

Contact details:

Heidi Douglass, Centre for Healthy Brain Ageing, 0435 579 202



More from this category

  • Environment, Medical Health Aged Care
  • 01/12/2023
  • 10:43
West Australian doctors peak bodies

WA doctors and health professionals call for the government to take urgent action on climate change and end fossil fuel expansion to protect health

On the 1st December, just prior to the COP28 Health Day on the 3rd December, representatives of the medical colleges for general practitioners (GPs), emergency doctors, rural and remote doctors, and surgeons, as well as other doctors and health professionals, gather at 8 am on the steps of Parliament House to call on the WA Government take urgent action on climate change and protect the health of Western Australians. Reiterating calls from medical colleges earlier this year in support of ending fossil fuel expansion and climate action, those gathered today ask the WA government to: End expansion of any new…

  • Medical Health Aged Care
  • 01/12/2023
  • 10:12
Australian Dental Industry Association

ADIA congratulates Senators of the Inquiry into the Provision of and Access to Dental Services in Australia

1 December The Australian Dental Industry Association congratulates the Senators of the Senate Select Committee Inquiry into the Provision of and Access to Dental…

  • Contains:
  • Medical Health Aged Care, Research Development
  • 01/12/2023
  • 09:17

Aegros Releases Top-Line Interim Clinical Trial Results of its COVID-19 Hyperimmune

Aegros Releases Top-Line Interim Clinical Trial Results of its COVID-19 Hyperimmune Aegros, an Australian clinical-stage biopharmaceutical company leader in the development and manufacture of plasma derived medicinal products (PDMPs), today announced positive top-line interim results from its CHAT clinical trial. Top-line interim results indicate that Aegros’ COVID-19 hyperimmune provides higher levels of antibodies compared to high-titer convalescent plasma. These results are in line with Aegros’ pre-clinical expectations. CHAT compared Aegros’ COVID-19 hyperimmune to COVID-19 convalescent plasma. The hyperimmune was manufactured using Aegros’ patented Haemafrac® process. A hyperimmune is an intravenous immunoglobulin rich in antibodies that can provide passive immunity for…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time your distribute with Medianet. Pay per release or save with a subscription.